There are in excess of 2 million nosocomial (hospital-acquired) infections every year in the United States.¹ Catheter-associated urinary tract infections (CAUTIs) comprise approximately 40% of all nosocomial infections.² Furthermore, CAUTIs comprise the largest reservoir of resistant organisms with healthcare facilities – a major threat to public health.³ As a leading provider of Foley urinary catheters, Bard has developed a novel solution to CAUTIs – the Bardex® I.C. Foley catheter with Bard® hydrogel and Bacti-Guard®* silver alloy coating. This unique Foley catheter has been found to dramatically reduce the incidence of CAUTIs by an average of 47% and provide a significant economic benefit to hospitals using the system.^{4 5} The Bardex® I.C. Foley catheter provides institutions with an innovative means to reduce costs and improve patient safety.

For more information, please contact us at:
Bard Medical Division
8195 Industrial Boulevard
Covington, GA 30014 USA
Phone: 1-800-526-4455
http://www.bardmedical.com/

Related Links:
Bard Urology

¹ www.cdc.gov/drugresistance/healthcare/problem.htm
² Salgado CD, Karchmer TB, Farr BM. Prevention of catheter-associated urinary tract infections. In Wenzel RP ed. Prevention and Control of Nosocomial Infections. 4th ed. Philadelphia: Lippincott Williams & Wilkins. 2003;297-311.
³ Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. Emerging Infectious Diseases. 2001;7:342-347.
⁴ Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Archives of Internal Medicine. 2000;160:3294-3298.
⁵ Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Archives of Internal Medicine. 2000;160:2670-2675.
*Bacti-Guard® silver alloy coating is licensed from Bactiguard AB.
Bacti-Guard is a registered trademark of Bactiguard AB.